|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for FRS3 |
 Gene summary |
| Basic gene Info. | Gene symbol | FRS3 |
| Gene name | fibroblast growth factor receptor substrate 3 | |
| Synonyms | FRS2-beta|FRS2B|FRS2beta|SNT-2|SNT2 | |
| Cytomap | UCSC genome browser: 6p21.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_006653.4, | |
| Description | FGFR substrate 3FGFR-signaling adaptor SNT2suc1-associated neurotrophic factor target 2 (FGFR signalling adaptor) | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 607744 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000137218 | ||
| HPRD : 06373 | ||
| Vega : OTTHUMG00000014686 | ||
| Protein | UniProt: O43559 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_FRS3 | |
| BioGPS: 10817 | ||
| Pathway | NCI Pathway Interaction Database: FRS3 | |
| KEGG: FRS3 | ||
| REACTOME: FRS3 | ||
| Pathway Commons: FRS3 | ||
| Context | iHOP: FRS3 | |
| ligand binding site mutation search in PubMed: FRS3 | ||
| UCL Cancer Institute: FRS3 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for FRS3 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | L60 | L60F | SKCM | 1 | V55 | A54V | SKCM | 1 | L47 | H48Y | UCEC | 1 | V55 | V55I | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for FRS3 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | V55 | A54V | -0.8117462 | L60 | L60F | -0.74947354 | V55 | V55I | -0.66552765 | L47 | H48Y | -0.52236747 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for FRS3 from PDB |
| Top |
| Differential gene expression and gene-gene network for FRS3 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for FRS3 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for FRS3 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of FRS3 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (LEU,PHE,ARG,LEU,ARG,HIS,PHE,PRO,CYS,GLY,ASN,VAL,ASN,TYR,GLY,TYR,GLN,GLN,GLN) | 2kup | A | L47 V55 L60 | III | Peptide ligand (LEU,PHE,ARG,LEU,ARG,HIS,PHE,PRO,CYS,GLY,ASN,VAL,ASN,TYR,GLY,TYR,GLN,GLN,GLN) | 2ys5 | A | L47 V55 L60 |
| Top |
| Conservation information for LBS of FRS3 |
| Multiple alignments for O43559 in multiple species |
| LBS | AA sequence | # species | Species | A88 | GQGIFAFKCSR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D129 | HPAELDLPRAP | 1 | Homo sapiens | D129 | HPPELDLPRGP | 1 | Mus musculus | D129 | HPQELDLPRGS | 1 | Rattus norvegicus | D27 | KVTNVDDEGVE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D28 | VTNVDDEGVEL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F74 | SNLFSFESGRR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F87 | TGQGIFAFKCS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F89 | QGIFAFKCSRA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F98 | RAEEIFNLLQD | 2 | Homo sapiens, Rattus norvegicus | F98 | RAEDIFNLLQD | 1 | Mus musculus | G66 | CLRRYGYDSNL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I86 | QTGQGIFAFKC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L33 | DEGVELGSGVM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L47 | QSELVLHLHRR | 1 | Homo sapiens | L47 | QSELVLHLHQR | 1 | Mus musculus | L47 | QSELVLHLHQQ | 1 | Rattus norvegicus | L60 | VRWPYLCLRRY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L62 | WPYLCLRRYGY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L71 | GYDSNLFSFES | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | M105 | LLQDLMQCNSI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N25 | KFKVTNVDDEG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Q102 | IFNLLQDLMQC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R63 | PYLCLRRYGYD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R64 | YLCLRRYGYDS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R79 | FESGRRCQTGQ | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S73 | DSNLFSFESGR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T82 | GRRCQTGQGIF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V26 | FKVTNVDDEGV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V55 | HRREAVRWPYL | 1 | Homo sapiens | V55 | HQREAVRWPYL | 1 | Mus musculus | V55 | HQQEAVRWPYL | 1 | Rattus norvegicus | W57 | REAVRWPYLCL | 2 | Homo sapiens, Mus musculus | W57 | QEAVRWPYLCL | 1 | Rattus norvegicus | Y59 | AVRWPYLCLRR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y65 | LCLRRYGYDSN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y67 | LRRYGYDSNLF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |